For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>Dolasetron(MDL-73147) is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting following chemotherapy.</p>
| Catalog Number | I000577 |
| CAS Number | 115956-12-2 |
| Synonyms | octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, 1H-indole-3-carboxylic acid, stereoisomer |
| Molecular Formula | C19H20N2O3 |
| Purity | ≥95% |
| Solubility | 10 mM in DMSO |
| Storage | -20°C |
| InChIKey | UKTAZPQNNNJVKR-MMUVGSQPSA-N |
| Reference | </br>1:Erratum: Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy [Erratum]. [No authors listed]Cancer Manag Res. 2016 Jun 28;8:83. doi: 10.2147/CMAR.S115369. eCollection 2016. PMID: 27390532 Free PMC Article</br>2:Long-term Use of Ondansetron, Dolasetron and Granisetron for the Prevention of Nausea and Vomiting: A Review of the Clinical Effectiveness and Safety [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Apr 23. PMID: 25610941 Free Books & Documents</br>3:Perioperative doses of ondansetron or dolasetron do not lengthen the QT interval. Obal D, Yang D, Sessler DI.Mayo Clin Proc. 2014 Jan;89(1):69-80. doi: 10.1016/j.mayocp.2013.10.008. PMID: 24388024 </br>4:Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD, Cox D.Support Care Cancer. 2014 Feb;22(2):469-77. doi: 10.1007/s00520-013-1999-9. Epub 2013 Oct 19. PMID: 24141698 Free PMC Article</br>5:Optimization of sample pretreatment methods for simultaneous determination of dolasetron and hydrodolasetron in human plasma by HPLC-ESI-MS. Hu Y, Chen S, Chen J, Liu G, Chen B, Yao S.J Chromatogr Sci. 2012 Oct;50(9):785-91. doi: 10.1093/chromsci/bms065. Epub 2012 May 29. PMID: 22645289 </br>6:Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy. Roberts SM, Bezinover DS, Janicki PK.Cancer Manag Res. 2012;4:67-73. doi: 10.2147/CMAR.S15545. Epub 2012 Feb 24. Erratum in: Cancer Manag Res. 2016;8:83. PMID: 22427733 Free PMC Article</br>7:Retraction note to: Dolasetron, but not metoclopramide prevents nausea and vomiting in patients undergoing laparoscopic cholecystectomy. Miller DR.Can J Anaesth. 2011 Sep;58(9):885, 885-6. doi: 10.1007/s12630-011-9531-5. English, French. No abstract available. PMID: 21792705 </br>8:Placebo-controlled comparison of dolasetron and metoclopramide in preventing postoperative nausea and vomiting in patients undergoing hysterectomy: Retraction. [No authors listed]Eur J Anaesthesiol. 2011 Jun;28(6):469. doi: 10.1097/EJA.0b013e328347b41c. No abstract available. PMID: 21540659 </br>9:Dolasetron for preventing postanesthetic shivering: Retraction. [No authors listed]Anesth Analg. 2011 May;112(5):1211. doi: 10.1213/ANE.0b013e31821a9648. Epub 2011 Mar 30. No abstract available. PMID: 21451086 </br>10:A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia. Vergne-Salle P, Dufauret-Lombard C, Bonnet C, Simon A, Trèves R, Bonnabau H, Bertin P.Eur J Pain. 2011 May;15(5):509-14. doi: 10.1016/j.ejpain.2010.09.013. Epub 2010 Oct 30. PMID: 21036635 |
